Background: The aim of this retrospective, single-arm study was to present the technique and preliminary efficacy and safety results of a single-fraction SBRT for LAPC using total intravenous anaesthesia and optical surface guidance as motion management. Methods: Fifty-five patients with locally advanced pancreatic cancer were treated with SBRT with a single-fraction receiving a median BED10= 128.9 Gy. Forty-two patients received systemic treatment. End points were OS, FFLP, PFS, and toxicity. Actuarial survival analysis and univariate analysis were investigated. Results: The median follow-up was 15 months, mean OS was 18 months (95% CI: 16.7 to 19.3), and the one-year FFLP and 1-year OS were 100% and 90.9% (95% CI: ± 1.5%), respectively. Median PFS was 12 months (95% CI: 9.5 to 14.4), and 1-year PFS was 85.5% (95% CI: ± 1.4%). Thirty-five patients (63.6%) were alive at the time of analysis. No acute/late toxicity > G2/G1 was reported. Conclusions: SBRT for LAPC using total intravenous anaesthesia and optical surface guidance presented as an effective and safe treatment with very low toxicity.
背景：本回顾性单臂研究旨在介绍采用全静脉麻醉联合光学表面引导作为运动管理手段的单次分割立体定向体部放疗（SBRT）治疗局部晚期胰腺癌的技术方案及初步疗效与安全性结果。方法：55例局部晚期胰腺癌患者接受单次分割SBRT治疗，中位生物等效剂量（BED10）达128.9 Gy，其中42例患者接受全身系统治疗。研究终点包括总生存期（OS）、局部无进展生存期（FFLP）、无进展生存期（PFS）及毒性反应。采用精算生存分析及单变量分析进行数据评估。结果：中位随访时间为15个月，平均总生存期为18个月（95% CI：16.7-19.3），1年局部无进展生存率与1年总生存率分别为100%和90.9%（95% CI：±1.5%）。中位无进展生存期为12个月（95% CI：9.5-14.4），1年无进展生存率为85.5%（95% CI：±1.4%）。数据分析时35例患者（63.6%）存活。未观察到>2级的急性毒性反应或>1级的晚期毒性反应。结论：采用全静脉麻醉联合光学表面引导的SBRT治疗局部晚期胰腺癌是一种安全有效的治疗方式，且毒性反应极低。
肿瘤(癌症)患者之家